SG10201509316SA - Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same - Google Patents

Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same

Info

Publication number
SG10201509316SA
SG10201509316SA SG10201509316SA SG10201509316SA SG10201509316SA SG 10201509316S A SG10201509316S A SG 10201509316SA SG 10201509316S A SG10201509316S A SG 10201509316SA SG 10201509316S A SG10201509316S A SG 10201509316SA SG 10201509316S A SG10201509316S A SG 10201509316SA
Authority
SG
Singapore
Prior art keywords
dopa
inhibitors
catechol
compositions
same
Prior art date
Application number
SG10201509316SA
Inventor
Oron Yacoby-Zeevi
Mara Nemas
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of SG10201509316SA publication Critical patent/SG10201509316SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG10201509316SA 2010-11-15 2011-11-15 Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same SG10201509316SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41363710P 2010-11-15 2010-11-15
US201161524064P 2011-08-16 2011-08-16

Publications (1)

Publication Number Publication Date
SG10201509316SA true SG10201509316SA (en) 2015-12-30

Family

ID=45478410

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013036678A SG190258A1 (en) 2010-11-15 2011-11-15 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
SG10201509316SA SG10201509316SA (en) 2010-11-15 2011-11-15 Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013036678A SG190258A1 (en) 2010-11-15 2011-11-15 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Country Status (26)

Country Link
US (6) US9421267B2 (en)
EP (3) EP2640358B1 (en)
JP (3) JP5902705B2 (en)
KR (1) KR101859242B1 (en)
CN (2) CN110123743A (en)
AU (1) AU2011330757B2 (en)
BR (1) BR112013011685B1 (en)
CA (1) CA2817888C (en)
CL (1) CL2013001368A1 (en)
CY (1) CY1120005T1 (en)
DK (2) DK3326615T3 (en)
ES (2) ES2660772T3 (en)
HR (2) HRP20180514T1 (en)
HU (2) HUE037005T2 (en)
IL (1) IL263954A (en)
LT (1) LT2640358T (en)
MX (1) MX348225B (en)
NZ (1) NZ610911A (en)
PL (2) PL2640358T3 (en)
PT (2) PT3326615T (en)
RS (1) RS57047B1 (en)
RU (2) RU2740080C2 (en)
SG (2) SG190258A1 (en)
SI (1) SI2640358T1 (en)
WO (1) WO2012066538A1 (en)
ZA (1) ZA201303509B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012315A (en) 2009-05-19 2011-12-16 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors.
JP5902705B2 (en) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyltransferase inhibitors, and compositions therefor
SI2640370T1 (en) 2010-11-15 2018-08-31 Neuroderm Ltd Weizmann Science Park Compositions for transdermal delivery of active agents
CA2875446A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd. Compositions comprising apomorphine and organic acids and uses thereof
HUE056006T2 (en) * 2013-03-13 2022-01-28 Neuroderm Ltd Combination for the treatment of parkinson's disease
WO2015115512A1 (en) * 2014-01-29 2015-08-06 独立行政法人産業技術総合研究所 Method for preparing water extract of ashwagandha leaves which has enhanced anti-cancer activity utilizing cyclodextrin, and pharmaceutical composition containing ashwagandha leaves
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) * 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
AU2015312430B2 (en) 2014-09-04 2020-06-25 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
CN111454290B (en) 2014-10-21 2022-12-23 艾伯维公司 Carbidopa and levodopa prodrugs and their use for treating parkinson's disease
MA41377A (en) 2015-01-20 2017-11-28 Abbvie Inc LEVODOPA AND CARBIDONA INTESTINAL GEL AND PROCEDURES FOR USE
DK3075723T3 (en) 2015-03-30 2017-09-11 Berlirem Gmbh High-resolution L-DOPA glycerol esters
EP3277660B1 (en) 2015-03-30 2019-10-16 Berlirem GmbH Water-soluble l-dopa esters
CA2984494A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
JP2019515908A (en) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド Carbidopa and L-dopa prodrugs and methods of use
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
CN106619490A (en) * 2017-01-19 2017-05-10 云南白药集团无锡药业有限公司 Levodopa transdermal patch and preparation method thereof
KR102437003B1 (en) * 2017-06-05 2022-08-26 디즐린 파마슈티컬스 아베 levodopa infusion solution
AU2018295533B2 (en) 2017-07-07 2021-07-22 Neuroderm Ltd Device for subcutaneous delivery of fluid medicament
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
CN111701024B (en) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 Levodopa preparation and preparation method and application thereof
CN111643493B (en) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 High-concentration levodopa preparation and preparation method and application thereof
US11213502B1 (en) * 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) * 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) * 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (en) * 1978-07-04 1985-05-28 三共株式会社 Method for manufacturing high concentration preparations of DOPAs
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE3779500T2 (en) 1986-06-10 1993-01-21 Chiesi Farma Spa LEVODOPA METHYL ESTER CONTAINING PHARMACEUTICAL COMPOSITIONS, THEIR PRODUCTION AND THERAPEUTIC USE.
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1992007561A1 (en) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
CA2327285C (en) 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (en) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (en) 2000-03-31 2000-03-31 Amarin Dev Ab Method of producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
JP2004522720A (en) * 2000-12-15 2004-07-29 ファイザー・インク Treatment of male sexual dysfunction
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
AU2002357137A1 (en) 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
AU2003214551A1 (en) 2002-04-11 2003-10-20 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10247233A1 (en) * 2002-10-10 2004-06-17 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New 4-substituted quinoline derivatives, useful for treating bacterial infections, optionally including additional ring nitrogens
BR0315221A (en) * 2002-10-10 2005-08-23 Morphochem Ag Komb Chemie Compounds with antibacterial activity
WO2005035088A2 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
US20050158374A1 (en) 2003-10-31 2005-07-21 Wong Patrick S. Compositions and dosage forms for enhanced absorption of metformin
WO2005099678A1 (en) * 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (en) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
SI1797109T1 (en) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060241183A1 (en) 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
EP1809283A2 (en) * 2004-10-01 2007-07-25 The Research Foundation Of State University Of New York Morphine and morphine precursors
DE102006021872B4 (en) * 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, process for their preparation and their use as medicaments
AU2007267135B2 (en) 2006-05-31 2013-03-07 AbbVie Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
US8563013B2 (en) 2007-04-06 2013-10-22 Janssen Biotech, Inc. Systems and methods for delivering a fluid drug
CN101669925B (en) 2008-09-10 2011-08-10 天津药物研究院 Dry powder inhalation, preparation method and application thereof
MX2011012315A (en) 2009-05-19 2011-12-16 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors.
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (en) 2010-07-16 2012-08-08 钟术光 Controlled release preparation
KR101187064B1 (en) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 Cationic lipid, method for manufacturing the same and delivery system comprising the same
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
SI2640370T1 (en) 2010-11-15 2018-08-31 Neuroderm Ltd Weizmann Science Park Compositions for transdermal delivery of active agents
JP5902705B2 (en) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyltransferase inhibitors, and compositions therefor
EP2648716A4 (en) 2010-12-10 2015-05-20 Synagile Corp Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
HUE056006T2 (en) 2013-03-13 2022-01-28 Neuroderm Ltd Combination for the treatment of parkinson's disease
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
SI2640358T1 (en) 2018-05-31
EP3326615B1 (en) 2020-01-08
HRP20180514T1 (en) 2018-05-04
EP2640358A1 (en) 2013-09-25
NZ610911A (en) 2015-02-27
RS57047B1 (en) 2018-05-31
SG190258A1 (en) 2013-06-28
DK3326615T3 (en) 2020-03-09
US20140249229A1 (en) 2014-09-04
AU2011330757A1 (en) 2013-06-06
CA2817888C (en) 2018-12-11
CY1120005T1 (en) 2018-12-12
HUE047841T2 (en) 2020-05-28
EP3326615A1 (en) 2018-05-30
CN110123743A (en) 2019-08-16
RU2013123457A (en) 2014-12-27
BR112013011685B1 (en) 2022-03-03
BR112013011685A2 (en) 2016-08-09
WO2012066538A1 (en) 2012-05-24
JP6387171B2 (en) 2018-09-05
JP6231145B2 (en) 2017-11-15
US9040577B2 (en) 2015-05-26
AU2011330757B2 (en) 2016-05-26
HUE037005T2 (en) 2018-08-28
US20230047523A1 (en) 2023-02-16
HRP20200366T1 (en) 2020-07-10
LT2640358T (en) 2018-03-26
US9040578B2 (en) 2015-05-26
CL2013001368A1 (en) 2014-09-05
JP5902705B2 (en) 2016-04-13
JP2018030877A (en) 2018-03-01
US20200397730A1 (en) 2020-12-24
US20170157077A1 (en) 2017-06-08
PL3326615T3 (en) 2020-07-27
MX2013005493A (en) 2013-09-06
JP2013545745A (en) 2013-12-26
US20140051755A1 (en) 2014-02-20
KR20130140075A (en) 2013-12-23
RU2740080C2 (en) 2021-01-11
IL263954A (en) 2019-01-31
PT2640358T (en) 2018-02-23
CN103442693A (en) 2013-12-11
MX348225B (en) 2017-05-31
KR101859242B1 (en) 2018-05-17
DK2640358T3 (en) 2018-04-16
RU2607497C2 (en) 2017-01-10
CA2817888A1 (en) 2012-05-24
EP2640358B1 (en) 2018-01-03
RU2016147575A3 (en) 2020-03-04
PT3326615T (en) 2020-03-23
US20140249228A1 (en) 2014-09-04
EP3692982A1 (en) 2020-08-12
ZA201303509B (en) 2014-12-23
JP2016106146A (en) 2016-06-16
RU2016147575A (en) 2018-10-23
PL2640358T3 (en) 2018-06-29
US9421267B2 (en) 2016-08-23
ES2776734T3 (en) 2020-07-31
ES2660772T3 (en) 2018-03-26

Similar Documents

Publication Publication Date Title
IL263954A (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
ZA201109037B (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK1246674A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
IL223865B (en) Calcium salts of dihydroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
IL226239B (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same